Physician
Portsmouth Hospital Corporation
Portsmouth Hospital Corporation was paid $19.69M by Medicaid between Jan 2018 and Dec 2024, across 204 billing codes. Its largest line is 99213, doctor's office visit, returning patient (routine) — 18% of everything it billed.
33Billing provider infoPORTSMOUTH HOSPITAL CORPORATION
PORTSMOUTH, OH 45662
PORTSMOUTH, OH 45662
33aNPI1417227398assigned 01/09/2012
33bProvider typeFamily Medicine Physician
28Total paid$19.69M
24GClaims451,399
24DCodes billed204
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Family Medicine Physician providers in Ohio
Rank by total paid#5 of 739
Median peer was paid$30K
This provider vs. median664×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official WHITLATCH, KRISTIE controls 18+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 33,640 | $818K | |
| 2019 | 34,304 | $516K | |
| 2020 | 33,956 | $1.33M | |
| 2021 | 60,665 | $3.24M | |
| 2022 | 73,439 | $4.35M | |
| 2023 | 109,699 | $4.91M | |
| 2024incomplete | 105,696 | $4.51M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 18% | 29,374 | 27,263 | $3.61M |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 17% | 21,416 | 19,506 | $3.26M |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 15% | 21,942 | 20,109 | $2.92M |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 7.1% | 7,660 | 6,960 | $1.39M |
| 80053 | Comprehensive metabolic panel | 3.7% | 31,065 | 26,559 | $730K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 3.4% | 1,414 | 1,257 | $660K |
| 96361 | Intravenous infusion, hydration; each additional hour | 2.4% | 1,001 | 835 | $475K |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 2.3% | 2,049 | 1,776 | $445K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.9% | 38,739 | 34,088 | $376K |
| 70450 | Computed tomography, head or brain; without contrast material | 1.4% | 675 | 601 | $280K |
| 84443 | Thyroid stimulating hormone (TSH) | 1.4% | 13,553 | 12,608 | $273K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.3% | 526 | 465 | $249K |
192 more codes
| 99284 | Emergency room visit (serious) | 1.2% | 1,017 | $244K |
| 99203 | Doctor's office visit, new patient (routine) | 1.2% | 2,149 | $237K |
| 84439 | 1.0% | 8,013 | $202K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 1.0% | 32,832 | $201K |
| 71046 | Radiologic examination, chest; 2 views | 1.0% | 6,355 | $198K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 566 | $195K |
| 82607 | <1% | 5,630 | $177K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 5,073 | $172K |
| 80061 | Lipid panel | <1% | 10,837 | $169K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 16,983 | $165K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 7,548 | $158K |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 1,431 | $157K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 7,113 | $136K |
| 87430 | <1% | 13,110 | $114K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 223 | $112K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 301 | $104K |
| 81001 | <1% | 16,471 | $104K | |
| 87081 | <1% | 12,286 | $101K | |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | <1% | 9,968 | $93K |
| 36415 | Collection of venous blood by venipuncture | <1% | 22,666 | $87K |
| 80047 | <1% | 4,514 | $85K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 3,559 | $82K |
| 99285 | Emergency room visit (most serious) | <1% | 336 | $78K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 502 | $77K |
| 82728 | <1% | 3,528 | $76K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 368 | $59K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 356 | $59K |
| 71250 | <1% | 329 | $56K | |
| 83550 | <1% | 4,209 | $54K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 3,826 | $53K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 420 | $46K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 1,252 | $43K |
| 52000 | <1% | 61 | $40K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 94 | $36K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 150 | $35K |
| 93017 | <1% | 240 | $32K | |
| 74018 | <1% | 787 | $32K | |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 44 | $30K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 101 | $29K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 2,520 | $29K |
| 72100 | <1% | 749 | $29K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 158 | $28K |
| 0223U | <1% | 91 | $27K | |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 1,425 | $27K |
| 84703 | <1% | 3,083 | $26K | |
| 80076 | <1% | 2,185 | $25K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 601 | $24K |
| 76536 | <1% | 152 | $23K | |
| 83735 | <1% | 2,456 | $23K | |
| 71271 | <1% | 107 | $23K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 574 | $22K |
| 73130 | <1% | 682 | $22K | |
| 73560 | <1% | 812 | $21K | |
| 73610 | <1% | 757 | $21K | |
| 73630 | <1% | 784 | $21K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 104 | $20K |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 227 | $18K |
| 73030 | <1% | 572 | $16K | |
| 86140 | <1% | 2,045 | $16K | |
| 84153 | <1% | 692 | $16K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 592 | $14K |
| 71101 | <1% | 165 | $14K | |
| G0378 | Hospital observation service, per hour | <1% | 203 | $13K |
| 86803 | <1% | 442 | $13K | |
| 87807 | <1% | 1,794 | $13K | |
| 82378 | <1% | 618 | $13K | |
| 80050 | General health panel | <1% | 205 | $12K |
| 72040 | <1% | 240 | $12K | |
| 82043 | <1% | 1,158 | $12K | |
| 85610 | <1% | 999 | $11K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 72 | $11K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 50 | $11K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 1,289 | $11K |
| 73110 | <1% | 416 | $11K | |
| 94729 | <1% | 87 | $10K | |
| 84403 | <1% | 313 | $9K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 1,192 | $9K |
| 88185 | <1% | 100 | $9K | |
| 88184 | <1% | 132 | $9K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 592 | $8K |
| 94726 | <1% | 69 | $8K | |
| 74450 | <1% | 96 | $8K | |
| 85652 | <1% | 1,270 | $7K | |
| 83690 | <1% | 2,646 | $7K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 1,537 | $7K |
| 84484 | <1% | 2,433 | $7K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 834 | $6K |
| 80074 | <1% | 249 | $6K | |
| 87186 | <1% | 859 | $6K | |
| 73502 | <1% | 193 | $6K | |
| 94060 | <1% | 24 | $5K | |
| 83880 | <1% | 803 | $5K | |
| 73221 | <1% | 12 | $5K | |
| 84145 | <1% | 1,604 | $5K | |
| 85730 | <1% | 829 | $4K | |
| 82746 | <1% | 467 | $4K | |
| 74019 | <1% | 185 | $4K | |
| 73080 | <1% | 117 | $4K | |
| 84270 | <1% | 148 | $4K | |
| 82150 | <1% | 282 | $3K | |
| 80069 | <1% | 107 | $3K | |
| 83970 | <1% | 99 | $3K | |
| 71045 | Radiologic examination, chest; single view | <1% | 381 | $3K |
| 86038 | <1% | 74 | $3K | |
| 93975 | <1% | 12 | $3K | |
| 87070 | <1% | 231 | $3K | |
| 84702 | <1% | 109 | $3K | |
| 93922 | <1% | 15 | $3K | |
| 85379 | <1% | 876 | $2K | |
| 86703 | <1% | 84 | $2K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 319 | $2K |
| 72070 | <1% | 68 | $2K | |
| 82947 | <1% | 745 | $2K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 29 | $2K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 28 | $2K |
| 84550 | <1% | 210 | $2K | |
| 82550 | <1% | 453 | $2K | |
| 82784 | <1% | 118 | $2K | |
| 43249 | <1% | 22 | $2K | |
| 87077 | <1% | 297 | $2K | |
| 84100 | <1% | 232 | $2K | |
| 82077 | <1% | 68 | $2K | |
| 70486 | <1% | 12 | $1K | |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 16 | $1K |
| 82565 | <1% | 126 | $1K | |
| 83605 | <1% | 852 | $1K | |
| 82570 | <1% | 85 | $1K | |
| 83525 | <1% | 30 | $1K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 2,689 | $1K |
| 86225 | <1% | 43 | $1K | |
| A9577 | Injection, gadobenate dimeglumine (multihance), per ml | <1% | 105 | $1K |
| 84156 | <1% | 115 | $899.05 | |
| 00910 | <1% | 648 | $861.52 | |
| 86900 | <1% | 28 | $860.47 | |
| 00170 | Anesthesia for intraoral procedures, including biopsy | <1% | 23 | $826.80 |
| 87210 | <1% | 216 | $735.06 | |
| 86003 | <1% | 18 | $692.61 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 2,177 | $658.15 |
| 84520 | <1% | 112 | $654.16 | |
| 80339 | <1% | 32 | $645.06 | |
| 99201 | <1% | 14 | $617.93 | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 180 | $612.75 |
| 85045 | <1% | 89 | $600.28 | |
| 86430 | <1% | 29 | $588.17 | |
| J2704 | Injection, propofol, 10 mg | <1% | 3,161 | $572.50 |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 19 | $544.35 |
| 88187 | <1% | 12 | $516.24 | |
| 97802 | <1% | 13 | $515.43 | |
| 96376 | <1% | 33 | $503.95 | |
| 86850 | <1% | 28 | $494.11 | |
| 97803 | <1% | 14 | $491.48 | |
| 87205 | <1% | 94 | $476.29 | |
| 83615 | <1% | 30 | $461.24 | |
| 72220 | <1% | 14 | $432.74 | |
| 73090 | <1% | 13 | $423.70 | |
| 86039 | <1% | 14 | $384.61 | |
| 86901 | <1% | 28 | $379.89 | |
| 86200 | <1% | 13 | $283.12 | |
| 80334 | <1% | 17 | $279.14 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 1,204 | $259.97 |
| 80337 | <1% | 17 | $245.19 | |
| 86308 | <1% | 15 | $232.28 | |
| 73140 | <1% | 14 | $223.15 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 1,407 | $199.59 |
| 84480 | <1% | 15 | $188.40 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 134 | $166.88 |
| 84165 | <1% | 28 | $159.23 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 811 | $152.84 |
| 99152 | <1% | 148 | $137.76 | |
| 80361 | <1% | 39 | $125.61 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 3,204 | $109.54 |
| 88300 | <1% | 15 | $102.00 | |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 66 | $93.00 |
| J3490 | Unclassified drugs | <1% | 68 | $88.61 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 2,567 | $84.02 |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 84 | $79.07 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 146 | $65.98 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | <1% | 371 | $65.93 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 3,027 | $62.73 |
| J0134 | Injection, acetaminophen (fresenius kabi), not therapeutically equivalent to j0131, 10 mg | <1% | 52 | $60.18 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 443 | $47.39 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 139 | $34.64 |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 66 | $23.91 |
| J1596 | Injection, glycopyrrolate, 0.1 mg | <1% | 31 | $14.24 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 22 | $8.81 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | <1% | 104 | $8.71 |
| J2470 | Injection, pantoprazole sodium, 40 mg | <1% | 22 | $7.06 |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | <1% | 79 | $2.81 |
| J1956 | Injection, levofloxacin, 250 mg | <1% | 217 | $2.50 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 187 | $1.62 |
| 00731 | 0% | 165 | $0.00 | |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | 0% | 19 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialWHITLATCH, KRISTIE (CEO)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.